Unlocking an expansive target space to build a pipeline of novel, TCR-based therapeutics.
At T-Cypher Bio we generate TCR-based therapeutics that have the potential to transform the treatment of solid tumours, autoimmune, inflammatory, and infectious diseases. T-Cypher’s proprietary automated high-throughput microfluidic discovery platform generates target screening libraries to identify functionally defined T-cell clones directly from disease tissues. The discovery platform forms the foundation of our expanding pipeline, which includes an end-to-end approach to cell therapy development and patient treatment.
Media
July 29, 2021
Formation of Scientific Advisory Board
July 15, 2021
Appointment of CEO
February 25, 2021
Biocentury
February 25, 2021
BioWorld
Our Team

His scientific background is in biomedical and biological engineering. His impact in academia recently culminated in establishing the Institute of Health Technology at the Technical University of Denmark with a patient-focused mission to innovate life changing health technologies. The Institute hosts over 500 researchers, and Thomas maintains a professorial position in drug engineering at the institute. He has co-authored over 200 research articles, is named on 45 patent applications and has received multiple research prizes including the Elite Research Price from the Danish Ministry of Science.

Mark holds a Masters of Biochemistry from the University of Oxford, a PhD in Genetics & Immunology from Imperial College London, and an MBA from the University of Oxford.

Nathaniel holds a PhD in Genetics from the University of Leicester, an MSci in Computer Science & Artificial Intelligence from Loughborough University, and carried out post-doctoral research at the University of Birmingham studying the immune evasion mechanisms of pancreatic cancer.

where, as a Scientist in Residence she was generating innovative new portfolio companies capable of tackling disease areas with major unmet need.
Prior to this Sarah was at Immunocore where she led a team of scientists to generate novel donor-unrestricted T cell therapeutics against oncology and infectious disease targets. She was also involved in the successful delivery of an HBV-bispecific to clinical trial for the treatment of chronic Hepatitis B.
Prior to Immunocore, Sarah held a Translational Research Fellowship with Ovacome at the University of Birmingham, where she worked on novel drugs and biomarkers to predict disease progression and chemo resistance in cancer patients. She has also held a number of post-doctoral positions, including with Janssen Pharmaceuticals where she delivered the pre-clinical package for an epigenetic drug combination that went into an acute myeloid leukaemia clinical trial.


Amalia holds a PhD from Imperial College London, having studied the relationship between cell size and gene expression using omics technologies. It is this knowledge that will contribute to bringing new TCR therapies to the clinic.

Juan next transitioned into industry as a tech development scientist in Orbit Discovery, where his experience helped develop peptide-protein display screening technologies. His experience in protein science and screening technologies provides a structural and biochemical perspective to the team to support HLA production and display development.
Juan holds a BSc and MSc in biomedical sciences and biochemistry from the Complutense University of Madrid in Spain, and then became a Marie Curie fellow at the University of Southampton to do his PhD, investigating how membrane lipids interact with ion channels to modulate function.

He then moved to Oxford University for a post-doctoral position at Oxford University's Weatherall Institute of Molecular Medicine (WIMM) in the Human Immunology Unit, where he carried out research on lipid antigen presentation to CD1-restricted T cell subsets under the late Prof Vincenzo Cerundolo. At the WIMM he also worked on projects related to tumour microenvironment (in the context of IDO+ tumours); this allowed further experience in traditional T cell assays and molecular/cellular biology techniques and also acquire new techniques (especially novel genome editing methods).
After moving to Immunocore, he employed and mastered genome editing techniques to generate cellular models for pre-clinical projects and for the assessment of new technologies and their deployment in assay development. Hema also led genome editing and new technologies teams which helped in understanding the biology of antigen presentation (in a T cell context), the validation/de-validation of novel immunotherapy targets, and implementation of new assays for antigens/therapeutics/effector functions discovery.

She holds an MSc in Neuroscience and Cognition from Utrecht University.









Prior to this, Eleanor completed her DPhil investigating the structure, function and inhibition of 2OG oxygenases involved in DNA modification and the hypoxic response. She also trained as an NHS Clinical Scientist in Clinical Biochemistry, based at the Imperial College Healthcare NHS Trust.
Eleanor has an MChem in Chemistry and a DPhil in Biochemistry from the University of Oxford, and an MSc in Clinical Biochemistry from the University of Manchester.

Beginning his career in the defence sector (Porton Down, Salisbury, UK) he has a natural instinct for QbD in ensuring all development activities are aligned to the final desired product. Throughout his career he has ensured that sophistication is dialled up during development, with a track record for identifying and implementing automation and disruptive technologies, all with the aim of massively simplifying technically complex methods, enabling those in late stage clinical/commercial manufacturing to focus on Quality

Previously, On spent 14 years at Oxford BioMedica mainly on generating special key reagents via out-sourcing and developing specific assays to support multiple pipeline products development. He holds a PhD in Biochemistry from the University of Manchester.
Board of Directors

His scientific background is in biomedical and biological engineering. His impact in academia recently culminated in establishing the Institute of Health Technology at the Technical University of Denmark with a patient-focused mission to innovate life changing health technologies. The Institute hosts over 500 researchers, and Thomas maintains a professorial position in drug engineering at the institute. He has co-authored over 200 research articles, is named on 45 patent applications and has received multiple research prizes including the Elite Research Price from the Danish Ministry of Science.

Phil has also spent over 20 years advancing innovation ecosystems at Dartmouth College and other universities. He is an adjunct professor at Dartmouth's Tuck School of Business, teaching venture capital topics.
Phil received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law, and a M.B.A. (with High Distinction) from the Tuck School of Business at Dartmouth.


Scientific Advisory Board


Tao originally gained a BSc degree in Physiology from Fudan University, Shanghai, China in 1987. She moved to Oxford University in 1993 where she received a DPhil degree in Immunology in 1998 for work carried out under the supervision of Professors Sarah Rowland-Jones and Sir Andrew McMichael on qualitative changes in HIV-specific cytotoxic T cells associated with HIV disease progression. During her postdoctoral training, where she continued to study immune responses to HIV, she expanded her research interests to include work on influenza virus infection, which led her to start her own independent research group. In 2010 she became the Head of the human anti-viral and anti-cancer cytotoxic T cell laboratory and subsequently Program Leader in the MRC Human Immunology Unit at Oxford University. Since 2013, her research has expanded to cancer, with a central goal being to identify determinants of the ability of human tumour-specific cytotoxic T cells to control human tumour development and metastasis. Since the start of the COVID-19 pandemic, Tao’s team has been working with colleagues in Oxford, UK and in China, testing samples taken from SARS-Cov-2 positive patients and trying to understand why some people with a COVID-19 infection are able to fight it off successfully, while others get really ill.

He and colleagues were first to show in 1998 that the non-classical non-polymorphic HLA class I molecule HLA-E presented a particular signal peptide to the natural killer cell receptor NKG2-CD94. Recently, it has been found that certain pathogens stimulate T cell responses restricted by HLA-E and his group have explored and explained how HLA-E can bind low affinity peptides to stimulate protective T cell responses. He has shown this to be the case in HIV and also SARS-CoV-2 infection. He has showed that such T cell responses are favoured when the processing of the signal peptide, which binds with higher affinity, is blocked. This opens up the possibility of universal immunotherapies targeting HLA-E with pathogen, self and cancer peptides, that he and his group are actively exploring.

PHOTO CREDIT THOMAS S. G. FARNETTI WELLCOME

